Newsletter Subject

How the availability of COVID-19 treatments has changed throughout the pandemic

From

arcamax.com

Email Address

ezines@arcamax.com

Sent On

Sat, Mar 19, 2022 05:01 AM

Email Preheader Text

Interesting slide shows about the world Slideshow World by Sponsor in National Consumer Center's $10

Interesting slide shows about the world Slideshow World by [ArcaMax](?ezine=782&r=XmZRwqdCss4pPuBidmGv3bgG_TCZvmVccfdprM09NuNDOjMyNzAwODM2NDpKOjIwOTQ3MjE6TDo3ODI6Ujo3MTY0NDE6Vjo0Ng) Sponsor [firstName]... What's Your Employment Situation? Are you... Under Employed? Unemployed? Over Employed? [Act now to participate]( in National Consumer Center's $1000 March Check Promotion. Pretty simple - All you do is answer a few questions about your employment situation - Takes less than 2 minutes. [Then, get a $1000 Check to help make ends meet]( details apply. So, to get started, [please follow this link.]( [How the availability of COVID-19 treatments has changed throughout the pandemic]( Betsy Ladyzhets [ How the availability of COVID-19 treatments has changed throughout the pandemic ]( [See full slideshow »]( At the beginning of the COVID-19 pandemic in March 2020, doctors had limited knowledge of how to respond to this new disease. Physicians in hard-hit regions across the world had to learn as they treated the first wave of patients, relying on ventilators and high-flow oxygen treatments, as well as early drugs such as hydroxychloroquine and remdesivir to reduce patients’ risk of dying. Years later, we have since seen several vaccines prove highly effective in preventing severe disease. The Pfizer/BioNTech, Moderna, and Johnson & Johnson vaccines were all developed in record time, building upon past research into coronavirus vaccines and genetic technology. In December 2021, unvaccinated adults in the U.S. were 2.4 times more likely to test positive for COVID-19 than fully vaccinated adults and were 14 times as likely to die of the disease, according to the Centers for Disease Control and Prevention. The likelihood of unvaccinated infection rose to 2.6 times as recently as January 2022. At the same time, pharmaceutical companies have developed a variety of drugs that may alleviate COVID-19 symptoms in those who test positive. Monoclonal antibody treatments provide a boost to the immune system, as patients receive infusions of lab-made proteins designed to fight off the coronavirus. In December 2021, the U.S. Food and Drug Administration provided emergency authorization to an antiviral pill treatment that reduces the risk of COVID-19 hospitalization and death. Both the monoclonal antibodies and pills are most effective when patients receive treatment soon after their COVID-19 symptoms begin. Relative to the fact that this is a novel disease never before known to medical science, progress in treatment development has been remarkably swift and agile. Stacker compiled a list of milestones in the availability of COVID-19 treatments and vaccines throughout the first two years of the pandemic, using information from the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, and media reports. Visit thestacker.com for similar lists and stories. © 2022 Stacker Media, LLC; Distributed by Tribune Content Agency, LLC [Tweet It]( - [Facebook It]( Sponsor [Get Your Goodie Box](... Free Samples and a lot more... Every Month we'll send you a box of free goodies and all you do is let us know what you think. Big Companies want to know how their 'next big thing' really works for you... And Shipping is Free. No credit card required EVER! Hurry we are sending out Goodie Boxes daily... [Sign up here - Free!]( And see if you qualify for a Goodie Box! [ Politics Digests: Right, Left And Everything In Between ] Politics Digests: Right, Left And Everything In Between Get political news, columns and editorial cartoons by subscribing below. Use the links to instantly subscribe: * [Righteous Right]( * [Proud Progressive]( * [Digest: Right, Left, Moderate]( * [Editorial Cartoons Only]( -- From the ArcaMax editors httpss://ww2.liveintent.com/ad-choices.html More Slideshow World from ArcaMax.com - [How wildfires have worsened in recent years]( - [How social media rebuilt advertising]( - [10 ways to build your brand on social media]( You Might Like [Learn more about RevenueStripe...]( [Click To Unsubscribe]( | [Customer Service]( | [Privacy Policy]( | [California / Nevada Privacy Info]( 11830 Canon Blvd. Ste A, Newport News, Va 23606 Copyright © 2022 ArcaMax Publishing [Facebook]( [Twitter](/ArcaMax)

Marketing emails from arcamax.com

View More
Sent On

23/05/2023

Sent On

22/05/2023

Sent On

22/05/2023

Sent On

22/05/2023

Sent On

22/05/2023

Sent On

22/05/2023

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.